1. Home
  2. FN vs GH Comparison

FN vs GH Comparison

Compare FN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabrinet

FN

Fabrinet

HOLD

Current Price

$495.69

Market Cap

16.1B

Sector

Utilities

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$104.95

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FN
GH
Founded
1999
2011
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.1B
13.3B
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
FN
GH
Price
$495.69
$104.95
Analyst Decision
Buy
Strong Buy
Analyst Count
8
21
Target Price
$489.14
$102.81
AVG Volume (30 Days)
787.0K
2.0M
Earning Date
02-02-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
16.68
N/A
EPS
10.43
N/A
Revenue
$3,892,507,000.00
$902,569,000.00
Revenue This Year
$33.48
$35.23
Revenue Next Year
$17.13
$27.38
P/E Ratio
$47.51
N/A
Revenue Growth
24.66
30.38
52 Week Low
$148.55
$34.88
52 Week High
$531.22
$120.74

Technical Indicators

Market Signals
Indicator
FN
GH
Relative Strength Index (RSI) 50.09 45.64
Support Level $458.07 $100.26
Resistance Level $512.38 $108.51
Average True Range (ATR) 33.97 5.98
MACD -1.64 -1.09
Stochastic Oscillator 53.05 31.71

Price Performance

Historical Comparison
FN
GH

About FN Fabrinet

Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: